ARS Pharmaceuticals (SPRY) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 31, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 0 added, 1 cutMore cutting

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about SPRY filings

Are insiders buying or selling ARS Pharmaceuticals, Inc (SPRY) stock?

Neither. ARS Pharmaceuticals, Inc (SPRY) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SPRY recently?

None. No member of Congress disclosed a SPRY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SPRY smart-money data?

This summary uses filings available on Oct 31, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on SPRY

Lean short1 source:
- Insiders
Neutral1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
- Alexander A Fitzpatrick, sold $33.5K, scheduled plan sale, filed Jun 13
- Eric Karas, sold $250K, scheduled plan sale, filed Jun 13
Lean short · thin2 sales · $284K
2 of 2 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
- Millennium, trimmed -$28.8M, holdings at Jun 30
- Millennium, added +$11.1M, holdings at Mar 31
Neutral · thin1 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SPRY filings

Are insiders buying or selling ARS Pharmaceuticals, Inc (SPRY) stock?

Neither. ARS Pharmaceuticals, Inc (SPRY) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SPRY recently?

None. No member of Congress disclosed a SPRY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SPRY smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$11.1MSells/Trims$28.8M

Buys/Adds (1)

MI
Millennium
Israel Englander · Q1 2026 13F
$11.1M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (1)

MI
Millennium
Israel Englander · Q2 2026 13F
$28.8M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 13, 2026

Earnings came in 27.7% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 13, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.63-27.70% miss

-$0.49 expected

Revenue

$33.7M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 9, 2026, in 9 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 13, 2026	-$0.63est. -$0.49	-27.70%miss	$33.7MSEC filing	+114.2%from $15.7M
Mar 31, 2026Reported May 15, 2026	-$0.61est. -$0.54	-14.02%miss	$22.7MSEC filing	+184.5%from $8.0M
Dec 31, 2025Reported Mar 9, 2026	-$0.42est. -$0.48	+12.50%beat	$28.1MYahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 10, 2025	-$0.52est. -$0.49	-6.12%miss	$32.5MSEC filing	+1471.6%from $2.1M
Jun 30, 2025Reported Aug 13, 2025	-$0.46est. -$0.51	+9.80%beat	$15.7MSEC filing	+3043.4%from $500.0K
Mar 31, 2025Reported May 14, 2025	-$0.35est. -$0.36	+2.78%beat	$8.0MSEC filing	No year-ago quarter
Dec 31, 2024Reported Mar 20, 2025	$0.51est. -$0.12	+$0.63beat	$89.1M · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 13, 2024	-$0.20est. -$0.14	-42.86%miss	$2.1MSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $3.62
52-wk high: $13.15
High: $3.79
52-wk low: $3.34
Low: $3.34
Prev close: $3.66
Mkt cap: $364.0M
ROE: -210.3%
Beta: 1.08
P/S: 3.1x
P/B: 29.0x
Profit margin: -184.2%
Op margin: -182.6%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -184.2%
Market cap: $364M

Valuation

P/S3.11
P/B29.01

Quality

Operating margin-182.6%
ROE-210.3%
ROA-48.0%

Growth

Beta1.08

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

29oversold

20D volatility

65%annualized

52-week range

$3.38

$3.34$13.15

20D support

$3.34recent floor

20D resistance

$4.63recent ceiling

Returns

5D -16.1%20D -17.0%60D -39.1%

Price vs moving averages

SMA20 -16.9%SMA50 -26.1%SMA200 -54.3%

Volume pace

1.10xvs prior 20D

Smart money at a glance

Filings to Oct 31, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 0 added, 1 cutMore cutting

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about SPRY filings

Are insiders buying or selling ARS Pharmaceuticals, Inc (SPRY) stock?

Neither. ARS Pharmaceuticals, Inc (SPRY) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SPRY recently?

None. No member of Congress disclosed a SPRY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SPRY smart-money data?

13F: filed up to 45 days late.

Smart money on SPRY

Lean short1 source:
- Insiders
Neutral1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
- Alexander A Fitzpatrick, sold $33.5K, scheduled plan sale, filed Jun 13
- Eric Karas, sold $250K, scheduled plan sale, filed Jun 13
Lean short · thin2 sales · $284K
2 of 2 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
- Millennium, trimmed -$28.8M, holdings at Jun 30
- Millennium, added +$11.1M, holdings at Mar 31
Neutral · thin1 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SPRY filings

Are insiders buying or selling ARS Pharmaceuticals, Inc (SPRY) stock?

Neither. ARS Pharmaceuticals, Inc (SPRY) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SPRY recently?

None. No member of Congress disclosed a SPRY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SPRY smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$11.1MSells/Trims$28.8M

Buys/Adds (1)

MI
Millennium
Israel Englander · Q1 2026 13F
$11.1M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (1)

MI
Millennium
Israel Englander · Q2 2026 13F
$28.8M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 13, 2026

Earnings came in 27.7% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 13, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.63-27.70% miss

-$0.49 expected

Revenue

$33.7M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 9, 2026, in 9 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 13, 2026	-$0.63est. -$0.49	-27.70%miss	$33.7MSEC filing	+114.2%from $15.7M
Mar 31, 2026Reported May 15, 2026	-$0.61est. -$0.54	-14.02%miss	$22.7MSEC filing	+184.5%from $8.0M
Dec 31, 2025Reported Mar 9, 2026	-$0.42est. -$0.48	+12.50%beat	$28.1MYahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 10, 2025	-$0.52est. -$0.49	-6.12%miss	$32.5MSEC filing	+1471.6%from $2.1M
Jun 30, 2025Reported Aug 13, 2025	-$0.46est. -$0.51	+9.80%beat	$15.7MSEC filing	+3043.4%from $500.0K
Mar 31, 2025Reported May 14, 2025	-$0.35est. -$0.36	+2.78%beat	$8.0MSEC filing	No year-ago quarter
Dec 31, 2024Reported Mar 20, 2025	$0.51est. -$0.12	+$0.63beat	$89.1M · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 13, 2024	-$0.20est. -$0.14	-42.86%miss	$2.1MSEC filing	No year-ago quarter

Open: $3.62
52-wk high: $13.15
High: $3.79
52-wk low: $3.34
Low: $3.34
Prev close: $3.66
Mkt cap: $364.0M
ROE: -210.3%
Beta: 1.08
P/S: 3.1x
P/B: 29.0x
Profit margin: -184.2%
Op margin: -182.6%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -184.2%
Market cap: $364M

Valuation

P/S3.11
P/B29.01

Quality

Operating margin-182.6%
ROE-210.3%
ROA-48.0%

Growth

Beta1.08

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

29oversold

20D volatility

65%annualized

52-week range

$3.38

$3.34$13.15

20D support

$3.34recent floor

20D resistance

$4.63recent ceiling

Returns

5D -16.1%20D -17.0%60D -39.1%

Price vs moving averages

SMA20 -16.9%SMA50 -26.1%SMA200 -54.3%

Volume pace

1.10xvs prior 20D

ARS Pharmaceuticals, Inc

Smart money at a glance

What do analysts expect?

Questions about SPRY filings

Smart money on SPRY

Questions about SPRY filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 27.7% below what analysts expected.

Estimated report: Nov 9, 2026, in 9 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

ARS Pharmaceuticals, Inc

Smart money at a glance

What do analysts expect?

Questions about SPRY filings

Smart money on SPRY

Questions about SPRY filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 27.7% below what analysts expected.

Estimated report: Nov 9, 2026, in 9 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

ARS Pharmaceuticals, Inc

Overview

Questions about SPRY filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

ARS Pharmaceuticals, Inc

Overview

Questions about SPRY filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.